{"Clinical Trial ID": "NCT00633464", "Intervention": ["INTERVENTION 1:", "Ixabepilone 40 mg/m^2", "ixabepilone 40 mg/m^2 every 3 weeks", "INTERVENTION 2:", "Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2", "- Load dose of cetuximab 400 mg/m^2 and then 250 mg/m^2 per week + ixabepilone 40 mg/m^2 every 3 weeks"], "Eligibility": ["Incorporation criteria:", "Female subjects with locally advanced non-resectable and/or metastatic triple negative breast cancer (ER, PR, and HER2 negative)", "Previous chemotherapy with adjuvant or neoadjuvant anthracycline", "- Exclusion criteria:", "Tumours that are positive or immunohistochemical (IHC) in situ fluorescence hybridization (FISH) tests 3+", "Neuropathy > Grade 1", "Previous systemic treatment for metastatic diseases"], "Results": ["Performance measures:", "Percentage of participants with an objective response (OR; using the criteria for assessing responses in solid tumours [RECIST])", "The confidence interval (CI) was calculated using the Clopper-Pearson method.", "Timeline: Evaluation every 6 weeks during the first 12 months of randomization thereafter every 3 months until disease progression (maximum objective response of participants of 18.3 weeks)", "Results 1:", "Title of the arm/group: Ixabepilone 40 mg/m^2", "Description of the arm/group: ixabepilone 40 mg/m^2 every 3 weeks", "Total number of participants analysed: 40", "Type of measurement: Number", "Unit of measure: percentage of participants 30.0 (16.6 to 46.5)", "Results 2:", "Title of the arm/group: Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2", "Description of the arm/group: cetuximab 400 mg/m^2 loading dose followed by 250 mg/m^2 per week + ixabepilone 40 mg/m^2 every 3 weeks", "Total number of participants analysed: 39", "Type of measurement: Number", "Unit of measure: percentage of participants 35.9 (21.2-52.8)"], "Adverse Events": ["Undesirable Events 1:", "Total: 9/40 (22.50 per cent)", "NEUTROPENIA FEBRILE 0/40 (0.00 %)", "NEUTROPENIA 0/40 (0.00 %)", "- TACHYCARDIA 0/40 (0.00 %)", "SINUS ARPHYTHMIA 1/40 (2.50%)", "STOMATITIS 0/40 (0.00 %)", "VOIX 1/40 (2.50%)", "- ABDOMINAL PEACE 0/40 (0.00 %)", "- RECTAL HEMORRHAGE 0/40 (0.00 %)", "GASTROINTESTINAL HEMORRHAGE 1/40 (2.50%)", "DIARRHOEA 0/40 (0.00 %)", "PYREXIA 2/40 (5.0%)", "- CHEST PEACE 0/40 (0.00 %)", "Adverse Events 2:", "Total: 12/37 (32.43 per cent)", "NEUTROPENIA FEBRILE 2/37 (5.41%)", "NEUTROPENIA 2/37 (5.41%)", "TACHYCARDIA 2/37 (5.41%)", "SINUS ARPHYTHMIA 0/37 (0.00 per cent)", "STOMATITIS 1/37 (2.70%)", "VOIX 1/37 (2.70%)", "ABDOMINAL PEACE 1/37 (2.70%)", "RECTAL HEMORRHAGE 1/37 (2.70%)", "GASTROINTESTINAL HEMORRHAGE 0/37 (0.00 %)", "DIARRHOEA 1/37 (2.70%)", "PYREXIA 0/37 (0.00 %)", "- CHEST PAIN 1/37 (2.70%)"]}